Literature DB >> 389528

Biliary excretion of drugs in man.

D E Rollins, C D Klaassen.   

Abstract

Biliary excretion is an important route for the elimination of some drugs and drug metabolites in man. The factors which determine elimination via the biliary tract include characteristics of the drug such as chemical structure, polarity and molecular size as well as characteristics of the liver such as specific active transport sites within the liver cell membranes. A drug excreted in bile may be reabsorbed from the gastrointestinal tract or a drug conjugate may be hydrolysed by gut bacteria, liberating original drug which can be returned to the general circulation. Enterohepatic circulation may prolong the pharmacological effect of certain drugs and drug metabolites, but the quantitative importance of this in man appears to be less than in animals. Biliary elimination may play a role in the interindividual differences in drug response observed in healthy subjects and in patients with certain diseases. Cholestatic disease states, in which normal bile flow is reduced, will influence drug elimination by this route resulting in increased risk of drug toxicity. Bile may serve as an alternate route of elimination in renal failure, but this has not been determined in man. Lack of reliable information regarding the biliary excretion of drugs in man is partly due to the relative inaccessibility of the human biliary tract. Most studies of drug excretion in human bile have been performed in post-surgical patients with T-tube drainage. This method of bile collection is not ideal because bile flow and composition are often severely altered during the period of study, not all bile is collected and enterohepatic circulation is partially interrupted. Recent advances in the methods of collection of bile may improve future studies of drug excretion in human bile.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 389528     DOI: 10.2165/00003088-197904050-00003

Source DB:  PubMed          Journal:  Clin Pharmacokinet        ISSN: 0312-5963            Impact factor:   6.447


  61 in total

1.  Studies on the intestinal excretion of doxycycline.

Authors:  K Alestig
Journal:  Scand J Infect Dis       Date:  1974

2.  Biliary excretion of 3H-terbutaline in man.

Authors:  H T Nilsson; C G Persson; K Tegner; I Ingemarsson; G Liedberg
Journal:  Biochem Pharmacol       Date:  1973-12-01       Impact factor: 5.858

3.  Biliary excretion of antibiotics in man.

Authors:  G Acocella; R Mattiussi; F B Nicolis; R Pallanza; L T Tenconi
Journal:  Gut       Date:  1968-10       Impact factor: 23.059

4.  The excretion of hexafluorenium in man and rat.

Authors:  D K Meijer; G A Vermeer; G Kwant
Journal:  Eur J Pharmacol       Date:  1971-05       Impact factor: 4.432

5.  Fate of orally administered 3H-digitoxin in man with special reference to the absorption.

Authors:  B Beermann; K Hellström; A Rosén
Journal:  Circulation       Date:  1971-06       Impact factor: 29.690

6.  Enterohepatic circulation of indomethacin and its role in intestinal irritation.

Authors:  D E Duggan; K F Hooke; R M Noll; K C Kwan
Journal:  Biochem Pharmacol       Date:  1975-10-01       Impact factor: 5.858

7.  Biliary excretion and enterochepatic recycling of proscillaridin A after oral adminstration to man.

Authors:  K E Andersson; B Bergdahl; G Wettrell
Journal:  Eur J Clin Pharmacol       Date:  1977-04-20       Impact factor: 2.953

8.  Biliary excretion of foreign compounds. Biphenyl, stilboestrol and phenolphthalein in the rat: molecular weight, polarity and metabolism as factors in biliary excretion.

Authors:  P Millburn; R L Smith; R T Williams
Journal:  Biochem J       Date:  1967-12       Impact factor: 3.857

9.  Antibiotics in biliary disease: the relative importance of antibiotic concentrations in the bile and serum.

Authors:  M R Keighley; R B Drysdale; A H Quoraishi; D W Burdon; J Alexander-Willians
Journal:  Gut       Date:  1976-07       Impact factor: 23.059

10.  Ioglycamide (Biligram) studies in man--plasma binding, renal and biliary excretion studies in jaundiced and anicteric patients.

Authors:  G D Bell; J McMullin; J Doran; J Oliver; J McAllister; A Monks; A Richens
Journal:  Br J Radiol       Date:  1978-04       Impact factor: 3.039

View more
  34 in total

Review 1.  Enterohepatic circulation: physiological, pharmacokinetic and clinical implications.

Authors:  Michael S Roberts; Beatrice M Magnusson; Frank J Burczynski; Michael Weiss
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

2.  Assessment of potential drug interactions by characterization of human drug metabolism pathways using non-invasive bile sampling.

Authors:  Jackie C Bloomer; Mike Nash; Alison Webb; Bruce E Miller; Aili L Lazaar; Claire Beaumont; William J Guiney
Journal:  Br J Clin Pharmacol       Date:  2013-02       Impact factor: 4.335

Review 3.  The role of beta-glucuronidase in drug disposition and drug targeting in humans.

Authors:  B Sperker; J T Backman; H K Kroemer
Journal:  Clin Pharmacokinet       Date:  1997-07       Impact factor: 6.447

Review 4.  Pharmacodynamic and kinetic considerations on diuretics as a basis for differential therapy.

Authors:  H Knauf; E Mutschler
Journal:  Klin Wochenschr       Date:  1991-04-04

5.  Estimation of biliary excretion of foreign compounds using properties of molecular structure.

Authors:  Mohsen Sharifi; Taravat Ghafourian
Journal:  AAPS J       Date:  2013-11-08       Impact factor: 4.009

Review 6.  Drug monitoring in nonconventional biological fluids and matrices.

Authors:  S Pichini; I Altieri; P Zuccaro; R Pacifici
Journal:  Clin Pharmacokinet       Date:  1996-03       Impact factor: 6.447

Review 7.  Predicting and Understanding the Human Microbiome's Impact on Pharmacology.

Authors:  Reese Hitchings; Libusha Kelly
Journal:  Trends Pharmacol Sci       Date:  2019-06-03       Impact factor: 14.819

Review 8.  Principles of pharmacotherapy: II. Pharmacokinetics.

Authors:  T J Pallasch
Journal:  Anesth Prog       Date:  1988 Jul-Aug

Review 9.  A risk-benefit assessment of flumazenil in the management of benzodiazepine overdose.

Authors:  A A Weinbroum; R Flaishon; P Sorkine; O Szold; V Rudick
Journal:  Drug Saf       Date:  1997-09       Impact factor: 5.606

10.  Metabolism of amitriptyline in patients with chronic renal failure.

Authors:  M Sandoz; S Vandel; B Vandel; B Bonin; B Hory; Y St Hillier; R Volmat
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.